NFKB1 and cancer: Additionally, we could hypothesise that, LA-EPS-20079 treatment counteracted the aggressive behaviour of cancer cell to attenuate the apoptotic canonical TGF-β-SMAD pathway and activated non-canonical TGF-β-NF-κB inflammatory signalling pathways.